What is B. Riley’s Estimate for KRMD FY2024 Earnings?

KORU Medical Systems, Inc. (NASDAQ:KRMD) – Investment analysts at B. Riley increased their FY2024 EPS estimates for shares of KORU Medical Systems in a report released on Tuesday, January 14th. B. Riley analyst K. Bauser now forecasts that the company will post earnings of ($0.13) per share for the year, up from their prior estimate of ($0.14). The consensus estimate for KORU Medical Systems’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for KORU Medical Systems’ Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.09) EPS.

Several other research analysts have also recently issued reports on KRMD. Piper Sandler lifted their target price on KORU Medical Systems from $3.00 to $3.50 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Craig Hallum upped their target price on shares of KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Canaccord Genuity Group boosted their price target on shares of KORU Medical Systems from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Finally, Lake Street Capital lifted their target price on shares of KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $4.30.

KORU Medical Systems Price Performance

Shares of NASDAQ KRMD opened at $4.00 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.99. The firm’s 50-day simple moving average is $3.77 and its 200 day simple moving average is $2.95. The stock has a market cap of $183.36 million, a price-to-earnings ratio of -16.00 and a beta of 0.45. KORU Medical Systems has a fifty-two week low of $1.98 and a fifty-two week high of $4.60.

Institutional Investors Weigh In On KORU Medical Systems

A number of hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of KORU Medical Systems during the 3rd quarter valued at $34,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of KORU Medical Systems by 77.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,412 shares of the company’s stock worth $168,000 after purchasing an additional 26,860 shares in the last quarter. Geode Capital Management LLC raised its position in shares of KORU Medical Systems by 6.5% in the third quarter. Geode Capital Management LLC now owns 462,128 shares of the company’s stock valued at $1,262,000 after purchasing an additional 28,323 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of KORU Medical Systems during the 2nd quarter valued at approximately $107,000. Finally, Empire Financial Management Company LLC bought a new position in KORU Medical Systems in the 3rd quarter worth approximately $259,000. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.